FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
64%chance▲ 10
Install
FDA decision: Ulixacaltamide by Praxis Precision Medicines (on or before January 29, 2027)
The odds
72%chance▼ 1
How the odds have moved
Yes: 73% on Nov 3, 72% now.
Each outcome's chance over time on Kalshi. The dots along the bottom are headlines about its subject: point at one to read it.
Every outcome
| Outcome | Chance | Day | Bid | Ask | Pays | Contracts |
|---|---|---|---|---|---|---|
| Yes | 72% | ▼ 1 | 68¢ | 76¢ | $1.32 |
"Pays" is what a $1 stake returns if that outcome happens, at the price shown (before any fees). Bid and ask are the best prices to sell and buy "Yes".
The news: FDA, Praxis Precision Medicines, Ulixacaltamide
Search ›- Praxis Precision Medicines (NASDAQ:PRAX) and Relay Therapeutics (NASDAQ:RLAY) Financial ReviewPosted by Defense World Staff on Oct 27th, 2026 Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) and Relay Therapeutics (NASDAQ:RLAY – Get Free Report) are both mid-cap healthcare companies, but which is the better stock? We will…
- Contrasting Relay Therapeutics (NASDAQ:RLAY) and Praxis Precision Medicines (NASDAQ:PRAX)Posted by Michael Walen on Oct 25th, 2026 Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) and Relay Therapeutics (NASDAQ:RLAY – Get Free Report) are both mid-cap healthcare companies, but which is the better investment? We will…
- RFK Jr. eases restrictions on some peptides not approved by FDACBS News Philadelphia is a local news organization that is part of CBS News and Stations. Also referred to as KYW-TV and channel 3, CBS News Philadelphia offers local breaking news, weather coverage and investigative reporting. RFK Jr…
- RFK Jr. eases restrictions on six peptides not approved by FDACBS News Texas is a local news organization that is part of CBS News and Stations. Also referred to as KTVT and channel 11, CBS News Texas offers local breaking news, weather coverage and investigative reporting. RFK Jr. eases restrictions…
- FDA zooms in on rare disease reviewsDelivered every Tuesday and Friday by 12 p.m., Prescription Pulse examines the latest pharmaceutical news and policy. 10/27/2026 12:00 PM EDT A NOT-SO ‘RARE’ FOCUS — The FDA’s recently announced effort to reimagine the review process for…
- FDA Approved an Antibiotic Based on Bogus Data -- but the Courts Don't CareUpdated on: February 18, 2011 / 6:34 PM EST / MoneyWatch The Ketek antibiotic scandal at Sanofi-Aventis (SNY) is receding into ancient history (if you agree that 2007 is "ancient"), so it's not until you read this new class action ruling…
- HIV prevention drug lenacapavir approved by FDA as twice-yearly injectionUpdated on: June 18, 2025 / 8:07 PM EDT / CBS News The U.S. Food and Drug Administration has approved the drug lenacapavir as a twice-yearly injection to prevent HIV. The drug, called Yeztugo from company Gilead Sciences, was approved…
- Trump admin eases access to unproven peptides favored by RFK Jr. despite FDA oppositionWASHINGTON — The Trump administration on Wednesday acted to ease access to unproven peptide drugs favored by Health Secretary Robert F. Kennedy Jr. Food and Drug Administration scientific staffers had little input on the decision and…
- Inside RFK Jr.'s push for pharmacies to make non-FDA approved peptidesCBS News is a trusted source for the latest in politics, U.S. and world news. The network is home to award-winning broadcasts CBS Mornings, CBS Evening News, 60 Minutes, CBS Sunday Morning, 48 Hours and Face the Nation.
- HHS green lights six peptides, despite concerns from FDA scientistsMeghana Keshavan is a biotech correspondent at STAT and co-writer of The Readout newsletter. She joined STAT in 2016. She has written about the life sciences industry for more than a decade. Before that, she worked for news outlets like…
- El-Sayed claps back at RFK Jr., and FDA’s ‘enforcement discretion’ on peptidesCare to test your knowledge of which fellas Trump thinks are hot? Send news tips and hunks to [email protected] or John_Wilkerson.07 on Signal. Abdul El-Sayed is the Democratic Senate candidate in Michigan. He’s also “a second-generation…
- Analysts Are Bullish on Top Healthcare Stocks: Abivax SA Sponsored ADR (ABVX), Humana (HUM)There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Abivax SA Sponsored ADR (ABVX), Humana (HUM) and Urogen Pharma (URGN) with bullish sentiments. Abivax SA Sponsored ADR (ABVX) In a report…
Related markets
All fda & drugs ›When will Compass Pathways submit a NDA for COMP360 psilocybin? (COMP360 psilocybin - NDA)
97%before April 2027
- before April 202797%▼ 1
- before 202794%▲ 2
- before December93%▲ 10
Will the FDA approve any psychedelic substance for medical use this year? (Before 2027)
13%chance▼ 5
When will Beam Therapeutics submit a BLA for Risto-cel?
70%before April 2027
- before April 202770%
- before 202746%▼ 1
- before December28%▲ 9
Will the FDA approve retatrutide? (retatrutide (LY3437943))
Dec 4, 2027even chance by
- Before Jan 1, 20271%
- Before Jul 1, 202721%▼ 2
- Before Jan 1, 202856%
2 more
- Before Jul 1, 202885%
- Before Jan 1, 202990%
When will the FDA reclassify BPC-157 to Category 1?
11%Before 2027
- Before 202711%▲ 1
Odds are traders' prices on Kalshi, Polymarket, ForecastEx and Crypto.com, not forecasts by 4Search. Prices read from the venues 11 min ago. Prices may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts. Not betting or investment advice.
Prediction-market prices are what traders pay for each outcome on Kalshi, Polymarket, ForecastEx and Crypto.com, read as the market's implied chance. They are not forecasts by 4Search, can move fast and can be wrong; they are read every few minutes and may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts at their price. News comes from the 4Search index; prices of stocks, rates and coins from 4Search Finance. Nothing here is betting, financial or investment advice. Terms of use. How to use Predictions